The therapeutic potential of immune cross-talk in leishmaniasis

Clinical Microbiology and Infection

Volumn 19, Issue 2, 2013, Pages 119-130

  Hartley, M A ^a   Kohl, K ^a   Ronet, C ^a   Fasel, N ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

HIV co infection; Hyperpathogenesis; Immune cross talk; Immunomodulatory antileishmanial agents; Immunophenotyping; Leishmania RNA virus; Leishmania Viannia; Leishmaniasis; Metastatic leishmaniasis; Nested co infection

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ARTEMISININ; AZITHROMYCIN; BCG VACCINE; CURCUMIN; DAPSONE; GLYCYRRHIZA GLABRA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIQUIMOD; ISOQUINOLINE ALKALOID; KALANCHOE PINNATA EXTRACT; MEGLUMINE ANTIMONATE; MILTEFOSINE; MOMORDICA CHARANTIA EXTRACT; PAROMOMYCIN; PENTAMIDINE; PENTOXIFYLLINE; PLANT EXTRACT; PYRAZINAMIDE; PYRROLE DERIVATIVE; RIFAMPICIN; TAMOXIFEN; TANNIN DERIVATIVE; TERPENE; THALIDOMIDE; TRITERPENE DERIVATIVE; TRITERPENE LACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 100;

CD4+ T LYMPHOCYTE; DRUG MECHANISM; GLYCYRRHIZA; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPATHOGENESIS; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; KALANCHOE; KALANCHOE PINNATA; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIA RNA VIRUS; LEISHMANIA VIANNIA; LEISHMANIN SKIN TEST; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MIXED INFECTION; MOLECULAR INTERACTION; MOMORDICA CHARANTIA; NONHUMAN; PATHOGENESIS; PHYLOGENY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RNA VIRUS; SKIN LEISHMANIASIS; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; TROPISM;

EID: 84873497121     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12095     Document Type: Review

References (98)

1. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010;xii-xiii, 1-186.
2. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clin Microbiol Infect 2011; 17: 1471-1477.
3. Alvar J, Velez ID, Bern C et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012; 7: e35671.
4. McCall LI, Matlashewski G. Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein. Mol Microbiol 2010; 77: 518-530.
5. Zhang WW, Matlashewski G. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci USA 1997; 94: 8807-8811.
6. Zhang WW, Mendez S, Ghosh A et al. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem 2003; 278: 35508-35515.
7. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 1997; 4: 530-535.
8. Hartley MA, Ronet C, Fasel N. Backseat drivers: the hidden influence of microbial viruses on disease. Curr Opin Microbiol 2012; 15: 538-545.
9. Hartley MA, Ronet C, Zangger H, Beverley SM, Fasel N. Leishmania RNA virus: when the host pays the toll. Front Cell Infect Microbiol 2012; 2: 1-15
10. Ronet C, Beverley SM, Fasel N. Muco-cutaneous leishmaniasis in the New World: the ultimate subversion. Virulence 2011; 2: 547-552.
11. Ives A, Ronet C, Prevel F et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011; 331: 775-778.
12. Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol 2011; 11: 187-200.
13. Barreto-de-Souza V, Pacheco GJ, Silva AR et al. Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis. J Infect Dis 2006; 194: 846-854.
14. Wortmann GW, Aronson NE, Miller RS, Blazes D, Oster CN. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000; 31: 199-201.
15. Saha P, Mukhopadhyay D, Chatterjee M. Immunomodulation by chemotherapeutic agents against leishmaniasis. Int Immunopharmacol 2011; 11: 1668-1679.
16. Li J, Sutterwala S, Farrell JP. Successful therapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production. Infect Immun 1997; 65: 3225-3230.
17. Nabors GS, Farrell JP. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. J Infect Dis 1996; 173: 979-986.
18. Ponte CB, Alves EA, Sampaio RN et al. Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL/6 mice. Int Immunopharmacol 2012; 13: 114-119.
19. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD Jr. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol 1987; 138: 744-749.
20. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
21. Nylen S, Akuffo H. Tracing immunity to human leishmaniasis. Future Microbiol 2009; 4: 241-254.
22. Alexander J, Brombacher F. T helper1/T helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol 2012; 3: 1-13
23. Carvalho EM, Johnson WD, Barreto E et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144-4148.
24. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol 2009; 31: 423-431.
25. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-655.
26. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol 2012; 24: 297-302.
27. Castellucci L, Jamieson SE, Almeida L et al. Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil. Infect Genet Evol 2012; 12: 1102-1110.
28. Kamali-Sarvestani E, Rasouli M, Mortazavi H, Gharesi-Fard B. Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients. Cytokine 2006; 35: 159-165.
29. de Jesus Fernandes Covas C, Cardoso CC, Gomes-Silva A, Oliveira JR, Da-Cruz AM, Moraes MO. Candidate gene case-control and functional study shows macrophage inhibitory factor (MIF) polymorphism is associated with cutaneous leishmaniasis. Cytokine 2013; 61: 168-172.
30. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 419-433.
31. Dimier-David L, David C, Ravisse P et al. Parasitological diagnosis of mucocutaneous leishmaniasis due to Leishmania b. braziliensis in Bolivia. Rev Soc Bras Med Trop 1991; 24: 231-234.
32. Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbieri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009; 63: 365-368.
33. Lessa HA, Machado P, Lima F et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65: 87-89.
34. Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002; 70: 6284-6293.
35. Murray HW, Moreira AL, Lu CM et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis 2003; 188: 458-464.
36. Badaro R, Lobo I, Munos A et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006; 194: 1151-1159.
37. Maurer-Cecchini A, Decuypere S, Chappuis F et al. Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials. Infect Immun 2009; 77: 2022-2029.
38. Negishi H, Yanai H, Nakajima A et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol 2012; 13: 659-666.
39. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010; 31: 154-163.
40. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007; 76: 447-480.
41. Wenzel UA, Bank E, Florian C et al. Leishmania major parasite stage-dependent host cell invasion and immune evasion. FASEB J 2012; 26: 29-39.
42. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 2005; 22: 415-426.
43. Shirazi MH, Ranjbar R, Asgari V, Mohebali M, Hamidian M. Study of bacterial infections among the patients with suspected cutaneous leishmaniasis. Pak J Biol Sci 2007; 10: 4555-4558.
44. Carlin AF, Chang YC, Areschoug T et al. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med 2009; 206: 1691-1699.
45. Ghoshal A, Mukhopadhyay S, Chava AK et al. 9-O-acetylated sialic acids enhance entry of virulent Leishmania donovani promastigotes into macrophages. Parasitology 2009; 136: 159-173.
46. Naik S, Bouladoux N, Wilhelm C et al. Compartmentalized control of skin immunity by resident commensals. Science 2012; 337: 1115-1119.
47. Gouveia C, Asensi MD, Zahner V, Rangel EF, Oliveira SM. Study on the bacterial midgut microbiota associated to different Brazilian populations of Lutzomyia longipalpis (Lutz & Neiva) (Diptera: Psychodidae). Neotrop Entomol 2008; 37: 597-601.
48. Azambuja P, Garcia ES, Ratcliffe NA. Gut microbiota and parasite transmission by insect vectors. Trends Parasitol 2005; 21: 568-572.
49. Schlein Y, Polacheck I, Yuval B. Mycoses, bacterial infections and antibacterial activity in sandflies (Psychodidae) and their possible role in the transmission of leishmaniasis. Parasitology 1985; 90 (Pt 1): 57-66.
50. Diaz-Albiter H, Sant'Anna MR, Genta FA, Dillon RJ. Reactive oxygen species-mediated immunity against Leishmania mexicana and Serratia marcescens in the sand phlebotomine fly Lutzomyia longipalpis. J Biol Chem 2012; 287: 23995-24003.
51. Theodos CM, Titus RG. Salivary gland material from the sand fly Lutzomyia longipalpis has an inhibitory effect on macrophage function in vitro. Parasite Immunol 1993; 15: 481-487.
52. Norsworthy NB, Sun J, Elnaiem D, Lanzaro G, Soong L. Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production. Infect Immun 2004; 72: 1240-1247.
53. Hall LR, Titus RG. Sand fly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric oxide production. J Immunol 1995; 155: 3501-3506.
54. Collin N, Gomes R, Teixeira C et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog 2009; 5: e1000441.
55. Gomes R, Teixeira C, Teixeira MJ et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci USA 2008; 105: 7845-7850.
56. Oliveira F, Lawyer PG, Kamhawi S, Valenzuela JG. Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl Trop Dis 2008; 2: e226.
57. Hillesland H, Read A, Subhadra B et al. Identification of aerobic gut bacteria from the kala azar vector, Phlebotomus argentipes: a platform for potential paratransgenic manipulation of sand flies. Am J Trop Med Hyg 2008; 79: 881-886.
58. Laurenti MD, Silveira VM, Secundino NF, Corbett CE, Pimenta PP. Saliva of laboratory-reared Lutzomyia longipalpis exacerbates Leishmania (Leishmania) amazonensis infection more potently than saliva of wild-caught Lutzomyia longipalpis. Parasitol Int 2009; 58: 220-226.
59. Iacobelli-Martinez M, Nepomuceno RR, Connolly J, Nemerow GR. CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines. J Virol 2005; 79: 11259-11268.
60. Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197: 7-17.
61. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek TB. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007; 26: 605-616.
62. Azeredo-Coutinho RB, Matos DC, Nery JA, Valete-Rosalino CM, Mendonca SC. Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res 2012; 45: 632-636.
63. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TB. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009; 10: 1081-1088.
64. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-359, table of contents.
65. Andreani G, Lodge R, Richard D, Tremblay MJ. Mechanisms of interaction between protozoan parasites and HIV. Curr Opin HIV AIDS 2012; 7: 276-282.
66. Cacopardo B, Nigro L, Preiser W et al. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Trans R Soc Trop Med Hyg 1996; 90: 434-435.
67. Wolday D, Berhe N, Britton S, Akuffo H. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. AIDS 2000; 14: 921-929.
68. Preiser W, Cacopardo B, Nigro L et al. Immunological findings in HIV-Leishmania coinfection. Intervirology 1996; 39: 285-288.
69. Zhao C, Thibault S, Messier N, Ouellette M, Papadopoulou B, Tremblay MJ. In primary human monocyte-derived macrophages exposed to human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake? J Gen Virol 2006; 87: 1295-1302.
70. Lodge R, Ouellet M, Barat C, Andreani G, Kumar P, Tremblay MJ. HIV-1 promotes intake of Leishmania parasites by enhancing phosphatidylserine-mediated, CD91/LRP-1-dependent phagocytosis in human macrophages. PLoS ONE 2012; 7: e32761.
71. Bernier R, Barbeau B, Tremblay MJ, Olivier M. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T cells through the nuclear factor-kappaB elements. J Immunol 1998; 160: 2881-2888.
72. Garg R, Lodge R, Descoteaux A, Tremblay MJ. Leishmania infantum promastigotes reduce entry of HIV-1 into macrophages through a lipophosphoglycan-mediated disruption of lipid rafts. J Infect Dis 2008; 197: 1701-1708.
73. Acestor N, Masina S, Ives A, Walker J, Saravia NG, Fasel N. Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis. J Infect Dis 2006; 194: 1160-1167.
74. Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011; 2011: ID 571242: 1-23.
75. University of Missouri. Jar in the Form of a Man with Disfigured Face. In: Museum of Art and Archaeology, Gift of Mr and Mrs Stanley Westreich. University of Missouri.
76. Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med 2007; 5: 1-14.
77. Dragicevic A, Dzopalic T, Vasilijic S et al. Signaling through Toll-like receptor 3 and Dectin-1 potentiates the capability of human monocyte-derived dendritic cells to promote T-helper 1 and T-helper 17 immune responses. Cytotherapy 2012; 14: 598-607.
78. Danaher RJ, Kaetzel CS, Greenberg RN, Wang C, Bruno ME, Miller CS. HIV protease inhibitors alter innate immune response signaling to double-stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome? AIDS 2010; 24: 2587-2590.
79. Abu-Shakra M, Shoenfeld Y. Chronic infections and autoimmunity. Immunol Ser 1991; 55: 285-313.
80. Pitta MG, Romano A, Cabantous S et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009; 119: 2379-2387.
81. Ansari NA, Kumar R, Gautam S et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol 2011; 186: 3977-3985.
82. Katara GK, Ansari NA, Singh A, Ramesh V, Salotra P. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL). PLoS Negl Trop Dis 2012; 6: e1703.
83. Bacellar O, Faria D, Nascimento M et al. Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis 2009; 200: 75-78.
84. Souza MA, Castro MC, Oliveira AP et al. American tegumentary leishmaniasis: cytokines and nitric oxide in active disease and after clinical cure, with or without chemotherapy. Scand J Immunol 2012; 76: 175-180.
85. Castellano LR, Llaguno M, Silva MV et al. Immunophenotyping of circulating T cells in a mucosal leishmaniasis patient coinfected with HIV. Rev Soc Bras Med Trop 2011; 44: 520-521.
86. Boaventura VS, Santos CS, Cardoso CR et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40: 2830-2836.
87. Bourreau E, Ronet C, Darsissac E et al. In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. J Infect Dis 2009; 199: 576-579.
88. Bourreau E, Ronet C, Darcissac E et al. Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun 2009; 77: 1465-1474.
89. Rodriguez-Pinto D, Navas A, Blanco VM et al. Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species. PLoS Negl Trop Dis 2012; 6: e1627.
90. Maurya R, Kumar R, Prajapati VK et al. Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen. Parasite Immunol 2010; 32: 479-483.
91. Rai AK, Thakur CP, Singh A et al. Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS ONE 2012; 7: e31551.
92. Arendse B, Van Snick J, Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005; 174: 2205-2211.
93. Nashed BF, Maekawa Y, Takashima M et al. Different cytokines are required for induction and maintenance of the Th2 type response in DBA/2 mice resistant to infection with Leishmania major. Microbes Infect 2000; 2: 1435-1443.
94. Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009; 10: 385-393.
95. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166: 1141-1147.
96. Ronet C, Hauyon-La Torre Y, Revaz-Breton M et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol 2010; 184: 886-894.
97. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-422.
98. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504-512.